| Literature DB >> 21959605 |
Sherry Megalla1, Dvorah Holtzman, Wilbert S Aronow, Reza Nazari, Svetlana Korenfeld, Aron Schwarcz, Ythan Goldberg, Daniel M Spevack.
Abstract
BACKGROUND: Some patients with right heart failure develop cardiac hepatopathy (CH). The pathophysiology of CH is thought to be secondary to hepatic venous congestion and arterial ischemia. We sought to define the clinical and hemodynamic characteristics associated with CH. MATERIAL/Entities:
Mesh:
Substances:
Year: 2011 PMID: 21959605 PMCID: PMC3539469 DOI: 10.12659/msm.881977
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Inclusions and exclusions.
Patient demographics and clinical variables.
| Patient demographics | All | Cardiac hepatopathy (n=56) | No cardiac hepatopathy (n=132) | p-value |
|---|---|---|---|---|
| Age (years) | 62±17 | 61±16 | 62±17 | 0.97 |
| Male (%) | 55 | 50 | 57 | 0.39 |
| Body surface area (m2) | 1.9±0.3 | 1.8±0.2 | 1.9±0.3 | 0.32 |
| Hypertension (%) | 81 | 86 | 79 | 0.26 |
| Diabetes (%) | 41 | 39 | 42 | 0.73 |
| Creatinine | 1.1 [1, 1.5] | 1.2 [1, 1.7] | 1.1 [1, 1.5] | 0.09 |
| Statin use (%) | 34 | 23 | 39 | 0.07 |
| Anti-platelet use (%) | 44 | 46 | 43 | 0.72 |
| ACEI or ARB use (%) | 46 | 46 | 45 | 0.90 |
| Beta blocker use (%) | 61 | 60 | 61 | 0.90 |
| Loop diuretic use (%) | 61 | 58 | 62 | 0.63 |
| Amiodarone use (%) | 2 | 5 | 1 | 0.14 |
| Warfarin use (%) | 24 | 17 | 27 | 0.22 |
| AST >100 mg/dL (%) | 13 | 45 | 0 | <0.001 |
| Alk-phos >200 mg/dL (%) | 14 | 48 | 0 | <0.001 |
| Total bilirubin >2.0 mg/dL (%) | 18 | 61 | 0 | <0.001 |
Normal data are presented as the mean ± standard deviation. Non-normal data are presented as the median [interquartile range]. ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; AST – aspartate aminotransferase; Alk-phos – alkaline phosphatase.
Etiology of right heart dysfunction.
| Patient demographics | All | Cardiac hepatopathy (n=56) | No cardiac hepatopathy (n=132) | p-value |
|---|---|---|---|---|
| Left heart failure (%) | 58 | 41 | 65 | 0.002 |
| Mitral valve disease (%) | 21 | 27 | 18 | 0.18 |
| Shunt (%) | 5 | 5 | 5 | 0.99 |
| Pulmonary hypertension (%) | 8 | 13 | 5 | 0.09 |
| Primary TR or PR (%) | 2 | 2 | 2 | 0.89 |
| Other etiology (%) | 7 | 13 | 5 | 0.05 |
TR – tricuspid regurgitation; PR – pulmonic regurgitation.
Echocardiographic and catheterization variables.
| Patient demographics | All | Cardiac hepatopathy (n=56) | No cardiac hepatopathy (n=132) | p-value |
|---|---|---|---|---|
| LV ejection fraction (%) | 30 [25, 50] | 30 [25, 50] | 30 [25, 50] | 0.48 |
| LA diameter (mm) | 48 ± 9 | 48±9 | 48±9 | 0.67 |
| Severe TR (%) | 23 | 21 | 24 | 0.68 |
| RV hypokinesis (%) | 80 | 73 | 83 | 0.11 |
| RV dilated (%) | 49 | 55 | 46 | 0.25 |
| RV systolic pressure (mmHg) | 55±18 | 58±18 | 54±18 | 0.13 |
| RV diastolic pressure (mmHg) | 14±7 | 16±7 | 13±7 | <0.001 |
| Cardiac output (Liters/min) | 3.9 [3.1, 4.7] | 4.0 [3.3, 5.0] | 3.7 [3.0, 4.6] | 0.08 |
| Wedge pressure (mmHg) | 22 [16, 28] | 24 [16, 28] | 22 [16, 28] | 0.43 |
Normal data are presented as the mean ± standard deviation. Non-normal data are presented as the median [interquartile range]. LV – left ventricular; LA – left atrial; TR – tricuspid regurgitation; RV – right ventricular.
Figure 2Prevalence of cardiac hepatopathy in those with and without left heart failure (LHF) divided amongst different cardiac output (CO) subgroups.